0001564590-22-034773.txt : 20221020 0001564590-22-034773.hdr.sgml : 20221020 20221020171539 ACCESSION NUMBER: 0001564590-22-034773 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20221020 ITEM INFORMATION: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221020 DATE AS OF CHANGE: 20221020 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 221321697 BUSINESS ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 BUSINESS PHONE: 7209402200 MAIL ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 8-K 1 abio-8k_20221020.htm 8-K abio-8k_20221020.htm
false 0000907654 0000907654 2022-10-20 2022-10-20

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 20, 2022

 

ARCA biopharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-22873

36-3855489

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

10170 Church Ranch Way, Suite 100, Westminster, CO

 

80021

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (720) 940-2200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

ABIO

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.08.

Shareholder Director Nominations.

 

 

On October 20, 2022, the board of directors (the “Board”) of ARCA biopharma, Inc., a Delaware corporation (the “Company”), approved December 15, 2022 as the date of the Company’s 2022 Annual Meeting of Stockholders (the “Annual Meeting”). The Board also approved October 25, 2022 as the record date for stockholders entitled to notice of and to vote at the Annual Meeting. Due to the fact that the Annual Meeting will be held more than 30 calendar days from the date of the Company’s 2021 Annual Meeting of Stockholders, the due dates for the provision of any qualified stockholder proposal or qualified stockholder nominations under the rules of the Securities and Exchange Commission (the “SEC”) and the bylaws of the Company listed in the Company’s 2021 Proxy Statement on Schedule 14A as filed with the SEC on April 21, 2021 are no longer applicable. Such nominations or proposals, including any notice on Schedule 14N, are now due to the Company no later than October 24, 2022. The Company currently intends to make its proxy materials available beginning on or about November 4, 2022.

 

Section 9 — Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

 

 

 

Exhibit Number

 

Description

 

 

104

 

Cover Page Interactive Data File. The cover page XBRL tags are embedded within the inline XBRL document (contained in Exhibit 101).

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 20, 2022

 

 

 

 

ARCA biopharma, Inc.

 

(Registrant)

 

 

 

 

By:

/s/ C. Jeffrey Dekker

 

 

Name:

C. Jeffrey Dekker

 

 

Title:

Chief Financial Officer

 

 

 

 EX-101.SCH 2 abio-20221020.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 abio-20221020_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 abio-20221020_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Oct. 20, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 20, 2022
Entity Registrant Name ARCA biopharma, Inc.
Entity Central Index Key 0000907654
Entity File Number 000-22873
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 36-3855489
Entity Address, Address Line One 10170 Church Ranch Way
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Westminster
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80021
City Area Code 720
Local Phone Number 940-2200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common
Trading Symbol ABIO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 abio-8k_20221020_htm.xml IDEA: XBRL DOCUMENT 0000907654 2022-10-20 2022-10-20 false 0000907654 8-K 2022-10-20 ARCA biopharma, Inc. DE 000-22873 36-3855489 10170 Church Ranch Way Suite 100 Westminster CO 80021 720 940-2200 false false false false Common ABIO NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports abio-8k_20221020.htm abio-20221020.xsd abio-20221020_lab.xml abio-20221020_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abio-8k_20221020.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "abio-8k_20221020.htm" ] }, "labelLink": { "local": [ "abio-20221020_lab.xml" ] }, "presentationLink": { "local": [ "abio-20221020_pre.xml" ] }, "schema": { "local": [ "abio-20221020.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "abio", "nsuri": "http://www.arcabiopharma.com/20221020", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "abio-8k_20221020.htm", "contextRef": "C_0000907654_20221020_20221020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "abio-8k_20221020.htm", "contextRef": "C_0000907654_20221020_20221020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20221020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001564590-22-034773-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-034773-xbrl.zip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end